EAU 2017: 4th ESO Prostate Cancer Observatory: Innovation and Care in the Next 12 Months

The “4th ESO Prostate Cancer Observatory: Innovation and Care in the Next 12 Months” was a standing-room only crowd with an international panel of experts highlighting important findings in prostate cancer research in 2016, and prognosticating what is to come in 2017.

Specifically, this included experts from basic science research, urologic oncology (discussing both surgery and active surveillance), radiology (discussing prostate MRI and PSMA-PET/CT), pathology, radiation oncology, medical oncology, and a unique patient perspective.  
The session was moderated by Drs. Van Poppel and Valdagni and the expert panelists presenting for the session included Drs. Zaffaroni, Tilki, Joniau, Moore, Van der Kwast, Bolla, De Santis, Haberkorn and Denis.
Hot topics included the use of liquid biopsy in patients with metastatic castration-resistant prostate cancer (mCRPC), the role of salvage lymph node dissection after radical prostatectomy, utilization of PSMA-PET/CT for diagnosis and treatment with radioactive agents, use of biomarkers and imaging to improve outcomes for patients undergoing active surveillance, updates on the ISUP Gleason grading system, and early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Stay tuned for additional, detailed updates from this exciting session.

Speakers: Drs. Van Poppel and Valdagni

Written By: Zachary Klaassen, MD, Urologic Oncology Fellow, University of Toronto, Princess Margaret Cancer Centre at #EAU17 London UK, March 24 - 28, 2017. 

Twitter: @zklaassen_md